Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...

The fund is sponsored by Vanguard. It has amassed assets over $153.57 billion, making it one of the largest ETFs attempting to match the Large Cap Growth segment of the US equity market. Fed officials ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

“With CRSP as the leading equities pricing data used by academic researchers, and OptionMetrics considered by many to be the ...

OptionMetrics and CRSP provide increased integration of U.S. equities and options data for use in academic research ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $41.92, demonstrating a -1.2% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a ...

CRISPR Therapeutics (CRSP) proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company’s annual general meeting to be ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...